Acute Myelogenous Leukemia Following Treatment with Cyclosporin A in a Nephrotic Patient.
スポンサーリンク
概要
- 論文の詳細を見る
We report here a very rare case of a nephrotic patient who developed acute myelogenous leukemia (AML, M2) 8 months after receiving cyclosporin A (CsA) therapy. A 30-year-old man with nephrotic syndrome had been taking diphenylhydantoin (DPH, 300 mg/day) for 6 years for treatment of convulsion and then received treatment of prednisolone and CsA (75 mg/day) for a nephrotic syndrome. Approximately 4 months after CsA therapy began, myeloblasts appeared in his peripheral blood at a ratio of 1%. Four months later, bone marrow aspiration and a biopsy confirmed a diagnosis of AML M2, showing hypercellular bone marrow with 60% leukemic cells. He received induction chemotherapy, which led to a complete remission.(Internal Medicine 41: 722-724, 2002)
- 社団法人 日本内科学会の論文
著者
-
Sano Masayuki
The Department Of Internal Medicine Saga Medical School
-
IKEDA Yuji
the Department of Internal Medicine, Saga Medical School
-
Sakemi Takanobu
The Department Of Internal Medicine Saga Medical School
-
Matsuzaki Miwako
The Department Of Internal Medicine Saga Medical School
-
Ikeda Yuji
The Department Of Internal Medicine Saga Medical School
-
SANO Masayuki
the Department of Internal Medicine, Saga Medical School
-
MATSUZAKI Miwako
The Department of Internal Medicine, Saga Medical School
関連論文
- Cellular Crescents and Segmental Glomerular Necrosis in IgA Nephropathy Are Indicative of the Beneficial Effects of Corticosteroid Therapy
- Acute Myelogenous Leukemia Following Treatment with Cyclosporin A in a Nephrotic Patient
- Acute Myelogenous Leukemia Following Treatment with Cyclosporin A in a Nephrotic Patient.
- Disseminated Intravascular Coagulation in Lupus Erythematosus with Acute Liver Damage.
- Cellular Crescents and Segmental Glomerular Necrosis in IgA Nephropathy Are Indicative of the Beneficial Effects of Corticosteroid Therapy.